India is experiencing a growing use of GLP-1 receptor agonists, such as Wegovy and Rybelsus, for weight loss, reflecting a shift towards the medicalization of obesity care amid rising overweight rates, with one in four Indian adults classified as overweight. However, concerns persist regarding regulatory loopholes, black-market sales, psychological dependence, side effects, and unequal access to these drugs. Eli Lilly has overtaken Novo Nordisk as a leading player in the anti-obesity medication market. Recent clinical research highlights the multifaceted benefits of GLP-1 receptor agonists, including appetite control, reduced systemic inflammation, improved lipid metabolism, anti-inflammatory effects, and potential cardiovascular benefits. Additionally, new treatments like ecnoglutide show promise for type 2 diabetes management. Meanwhile, studies indicate that statins, a highly profitable drug class with annual sales exceeding $20 billion, may reduce GLP-1 levels, which could have implications for metabolic health. The incretin hormones GLP-1 and GIP are recognized as critical links between digestion and metabolism, further emphasizing the importance of these pathways in obesity and cardiovascular disease treatment.